NEWTON, Mass.--(BUSINESS WIRE)--InnovationRx, a wholly owned subsidiary of Innovation Group (LSE: TiG), announced today that it has partnered with Advanced BioHealing, Inc. (ABH) to conduct a pilot program providing support for patients receiving Dermagraft® treatment. Dermagraft, which is manufactured and marketed by ABH, is a human derived dermal substitute approved by the FDA for the treatment of diabetic foot ulcers (DFU). The pilot program, which will launch in Dallas and be tested in other U.S. cities, will assist both patients and healthcare providers in addressing various issues that negatively impact patient compliance during their treatment for diabetic foot ulcers. The goal of this pilot program is to determine whether a program can be developed that addresses some of the cultural and socioeconomic issues that tend to plague patients with active DFU’s and improve the overall treatment outcome.
